HER2 Z00342 / Affibody - LARVOL DELTA

Designed Ankyrin Repeat Protein-Mediated Peptide Nucleic Acid-Based Pretargeting: A Proof-of-Principle Study. (PubMed, J Nucl Med) - "The biodistribution and the tumor uptake of [177Lu]Lu-HP2 were strikingly similar in the cases of Affibody- and DARPin-based pretargeting. Sortase A-mediated coupling enables the development of a PNA-based pretargeting system for DARPin G3, expanding the application of this approach to another class of ESPs."

Journal • Oncology • HER-2

Anti-breast cancer activity of a novel genetically engineered fusion protein composed of HER2 affibody and proapoptotic peptide R8-KLA. (PubMed, Med Oncol) - "Caspase inhibitor Z-VAD significantly reversed the function of HMK in SK-BR-3 cells, suggesting that caspase-dependent apoptosis was crucial for the anti-breast cancer activity of HMK. Our results suggested that HMK protein may have the potential to become a candidate molecule for HER2-positive breast cancer treatment."

Journal • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor • CASP3 • CASP8 • CASP9 • HER-2

Covalent Affibody-Molecular Glue Drug Conjugate Nanoagent for Proximity-Enabled Reactive Therapeutics. (PubMed, Adv Sci (Weinh)) - "Such a covalent binding mode endows ZHER2:342-36FSY-CR8 ADCN with permanent binding ability to effectively increase the concentration of drugs in tumor. Eventually, the covalent ZHER2:342-36FSY-CR8 ADCN exhibits an outstanding tumor inhibition ratio of 90.03 ± 4.29% in HER2-positive ovary tumor models, strikingly higher than that of the noncovalent one (64.25 ± 7.71%)."

Journal • Oncology • Ovarian Cancer • Targeted Protein Degradation • HER-2

A novel HER2 targeting nanoagent self-assembled from affibody-epothilone B conjugate for cancer therapy. (PubMed, J Nanobiotechnology) - "Moreover, the abundant presence of ZHER2:342 on the surface effectively enhances the targeting capacity and tumor accumulation of the drug. Z-E ADCN can be internalized by cancer cells via HER2 receptor-mediated endocytosis followed by Epo B release in response to high levels of ROS, resulting in excellent anticancer efficacy in HER2-positive tumor models."

Journal • Oncology • HER-2

Albumin incorporation into recognising layer of HER2-specific magnetic nanoparticles as a tool for optimal targeting of the acidic tumor microenvironment. (PubMed, Heliyon) - "In vivo experiments revealed that after i.v. administration, BSA-decorated nanoparticles exhibited 2 times higher accumulation in tumors compared to magnetic nanoparticles modified with affibody only. Thus, we demonstrated a valid method for enhancing the specificity of targeted nanoparticle delivery to cancer cells without changing the functional components of nanoparticles."

Biomarker • Journal • Tumor microenvironment • Oncology • HER-2

The effect of Fc region affinity of protein-based antibody-recruiting molecules on antibody-dependent cellular cytotoxicity. (PubMed, RSC Adv) - "Furthermore, the required residence time of the complex between Fc-ARM and IgG was ∼102 min, which was comparable to that when monoclonal antibodies bind to their specific antigens. However, we found that the extent of ADCC induced by Fc-ARM was lower than that of conventional IgG-mediated ADCC, indicating that further enhancement of the affinity of the antibody-binding terminus and tumor-binding terminus of Fc-ARM may be needed to achieve ADCC equivalent to that of conventional IgG-mediated ADCC."

Journal • Oncology • HER-2

Shorter Peptide Nucleic Acid Probes Improve Affibody-Mediated Peptide Nucleic Acid-Based Pretargeting. (PubMed, ACS Pharmacol Transl Sci) - "This suggests that using a shorter 9-mer primary probe, Z-HP9, in combination with 9-mer HP16 or 8-mer HP20 secondary probes effectively targets tumors while minimizing the dose-limiting kidney uptake of radionuclide. In conclusion, the Z-HP9:HP16 and Z-HP9:HP20 probe combinations offer good prospects for both cost-effective production and efficient in vivo pretargeting of HER2-expressing tumors."

Journal • Oncology • HER-2

Affibody-mediated PNA-based pretargeted co-treatment improves survival of trastuzumab-treated mice bearing HER2-expressing xenografts. (PubMed, J Nucl Med) - " Treatment of mice bearing HER2-expressing xenografts with the combination of trastuzumab and affibody-mediated PNA-based radionuclide pretargeting significantly increased the survival compared to monotherapies. Co-treatment was not toxic for normal tissues."

Journal • Preclinical • Oncology • HER-2